Caroline Irene Piatek, MD

Clinical Associate Professor of Medicine (Clinician Educator)

Hematology/Oncology Fellowship Program Director

Service Chief for Hematology at LAC+USC

Image of Caroline Irene Piatek, MD
Is this your profile? Click to edit


Dr. Carolne Piatek is an Associate Professor in the Jane Anne Nohl Division of Hematology at the Keck School of Medicine of USC. She is currently the fellowship director for the USC/LAC+USC Medical Hematology Fellowship Program. Dr. Piatek’s clinical focus is in non-malignant hematology. Her research interests include immune thrombocytopenia, warm autoimmune hemolytic anemia, cancer-associated thrombosis and paroxysmal nocturnal hemoglobinuria.

After earning her medical degree from Creighton University School of Medicine, Dr. Piatek completed internal medicine residency and hematology/medical oncology fellowship at the University of Southern California.


  • Keck School of Medicine of USC: Hematology Chief Fellow, 2014-2015
  • American Society of Clinical Oncology: Conquer Cancer Foundation Merit Award, 2014
  • USC: Medical Oncology Fellow Research Award, 2012-2013


  • Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD) Am J Hematol. 2024 Jan; 99(1):79-87. . View in PubMed
  • Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial Lancet Haematol. 2023 Dec; 10(12):e955-e965. . View in PubMed
  • Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up Adv Ther. 2023 Jan; 40(1):211-232. . View in PubMed
  • One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab Eur J Haematol. 2021 Mar; 106(3):389-397. . View in PubMed
  • A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia Acta Haematol. 2020; 143(3):244-249. . View in PubMed
  • Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria PLoS One. 2020; 15(9):e0237497. . View in PubMed
  • Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study Blood. 2019 02 07; 133(6):540-549. . View in PubMed
  • Case Report: Oxaliplatin-Induced Immune-Mediated Thrombocytopenia Case Rep Oncol. 2018 Sep-Dec; 11(3):880-882. . View in PubMed
  • Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome Acta Haematol. 2017; 138(3):129-137. . View in PubMed
  • Value of routine staging imaging studies for patients with stage III breast cancer J Surg Oncol. 2016 Dec; 114(8):917-921. . View in PubMed
  • OC-14 – Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin Thromb Res. 2016 Apr; 140 Suppl 1:S174. . View in PubMed
  • An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians Korean J Fam Med. 2015 Sep; 36(5):197-202. . View in PubMed
  • Management of immune-mediated cytopenias in pregnancy Autoimmun Rev. 2015 Sep; 14(9):806-11. . View in PubMed
  • Thrombocytopenia: optimizing approaches in cancer patients Oncology (Williston Park). 2015 Apr; 29(4):297-8. . View in PubMed
  • Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors Cancer Chemother Pharmacol. 2014 Dec; 74(6):1227-34. . View in PubMed
  • Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature Hum Pathol. 2014 Nov; 45(11):2183-91. . View in PubMed
  • Unsuspected pulmonary embolism: impact on mortality among cancer patients Curr Opin Pulm Med. 2012 Sep; 18(5):406-9. . View in PubMed
  • Treating venous thromboembolism in patients with cancer Expert Rev Hematol. 2012 Apr; 5(2):201-9. . View in PubMed
  • Genetic screens for enhancers of brahma reveal functional interactions between the BRM chromatin-remodeling complex and the delta-notch signal transduction pathway in Drosophila Genetics. 2005 Aug; 170(4):1761-74. . View in PubMed